MedTrace Logo

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NCT04830826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1490

Last updated 2025-07-30

No results posted yet for this study

Summary

This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR Mutation-Positive in the real world. The secondary purpose was to observe the postoperative follow-up treatment pattern and its subgroups (based on different EGFR mutation status and different clinical stages).

Conditions

  • NSCLC, Stage I
  • NSCLC, Stage II
  • NSCLC, Stage III

Interventions

PROCEDURE

Surgeries

Surgeries

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • jianxing He, President · The First Affiliated Hospital of Guangzhou Medical University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-09
Primary Completion
2024-07-08
Completion
2025-04-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830826 on ClinicalTrials.gov